secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2022-06-27T23:59:59+00:00
Accession:  0000950170-22-012194
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Phase 2 MISSION trial: 64.7% overall renal response rate in lupus nephritis
--------------------------------------------------------------------------------

- 11 of 17 patients (64.7%) achieved overall renal response (≥50% reduction in UPCR) at 6 months.
- 6 of 17 patients (35.2%) achieved complete renal response (UPCR ≤0.5, eGFR stable, steroids ≤10 mg/day).
- Zetomipzomib well tolerated; most AEs mild-to-moderate; no Grade 3 infections reported.
- Mean daily prednisone reduced from 19.2 mg at baseline to 9.1 mg at end of treatment.
- Company plans continued development for lupus nephritis and evaluation for systemic lupus erythematosus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022012194/0000950170-22-012194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022012194/kzr-20220627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer